Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-04-19
2011-04-19
Bristol, Lynn (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07928214
ABSTRACT:
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
REFERENCES:
patent: 5597725 (1997-01-01), Suzuki
patent: 5610281 (1997-03-01), Brenner et al.
patent: 5646250 (1997-07-01), Suzuki
patent: 5811518 (1998-09-01), Ranscht
patent: 5863804 (1999-01-01), Ranscht
patent: 5895748 (1999-04-01), Johnson et al.
patent: 5997866 (1999-12-01), Johnson et al.
patent: 6031072 (2000-02-01), Blaschuk et al.
patent: 6146630 (2000-11-01), Tsubota et al.
patent: 6169071 (2001-01-01), Blaschuk et al.
patent: 6203788 (2001-03-01), Blaschuk et al.
patent: 6207639 (2001-03-01), Blaschuk et al.
patent: 6248864 (2001-06-01), Blaschuk et al.
patent: 6277824 (2001-08-01), Doherty et al.
patent: 6280739 (2001-08-01), Jacobs et al.
patent: 6300080 (2001-10-01), Brenner et al.
patent: 6310177 (2001-10-01), Blaschuk et al.
patent: 6312686 (2001-11-01), Staddon et al.
patent: 6312921 (2001-11-01), Jacobs et al.
patent: 6326352 (2001-12-01), Blaschuk et al.
patent: 6333307 (2001-12-01), Blaschuk et al.
patent: 6346512 (2002-02-01), Blaschuk et al.
patent: 2002/0009739 (2002-01-01), Giese
patent: 2004/0110712 (2004-06-01), Markowitz
patent: 2005/0129676 (2005-06-01), Blaschuk et al.
patent: 2006/0039915 (2006-02-01), Reinhard et al.
patent: 2006/0040302 (2006-02-01), Botstein et al.
patent: 11 292900 (1999-10-01), None
patent: WO 91/04745 (1991-04-01), None
patent: WO 92/17608 (1992-10-01), None
patent: WO 93/21302 (1993-10-01), None
patent: WO 94/11401 (1994-05-01), None
patent: WO 95/13820 (1995-05-01), None
patent: WO 98/02452 (1998-01-01), None
patent: WO 98/16241 (1998-04-01), None
patent: WO 98/25946 (1998-06-01), None
patent: WO 99/08717 (1999-02-01), None
patent: WO 99/16791 (1999-04-01), None
patent: WO 00/78941 (2000-12-01), None
patent: WO 01/25492 (2001-04-01), None
patent: WO 02/08765 (2002-01-01), None
patent: WO 02/059264 (2002-08-01), None
patent: WO 02/097395 (2002-12-01), None
patent: WO 2004/018648 (2004-03-01), None
patent: WO 2004/044000 (2004-05-01), None
patent: 2004/003019 (2004-06-01), None
patent: WO 2004/003019 (2004-06-01), None
patent: WO 2004/072117 (2004-08-01), None
patent: WO 2004/110345 (2004-12-01), None
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Ward et al. (Nature 341:544-546 (1989)).
Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)).
Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)).
Song et al. (Biochem Biophys Res Comm 268:390-394 (2000)).
Bussemakers, M., et al., “Complex Cadherin Expression in Human Prostate Cancer Cells,” InternationalJournal of Cancer, 2000, 446-450, vol. 85, No. 3.
De Boer, C., et al., “Changing Roles of Cadherins and Catenins during Progression of Squamous Intraepithelial Lesions in the Uterine Cervix,”American Journal of Pathology, 1999, 505-515, vol. 155, No. 2.
Furukawa, F., “Roles of E- and P-Cadherin in the Human Skin,”Microscopy Res&Tech(1997) 343-352, vol. 38.
Gumbiner, B.M., “Regulation of Cadherin Adhesive Activity,”J. Cell Bio.(2000) 399-403, vol. 148, No. 3.
Gamallo, C., et al., “The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma,”Modern Pathology(2001), 650-654, vol. 14.
Hardy, R.G., et al., “Aberrant P.-Cadherin Expression is an Early Event in Hyperplastic and Dysplastic Transformation in the Colon,”Gut(2002) 513-519, vol. 50.
Hines, M., et al, “Inhibition of Cadherin Function Differentially Affects Markers of Terminal Differentiation in Cultured Human Keratinocytes,”Journal of Cell Science, 1999, 4569-4579, vol. 112, No. 24.
Hirai, Y., et al., “Expression and Role of E- and P-Cadherin Adhesion Molecules in Embryonic Histogenesis,”Development, 1989, 263-270, vol. 105, No. 2.
Jankowski, J., et al., “Alterations in Classical Cadherins Associated with Progression in Ulcerative and Crohn's Colitis,”Laboratory Investigations, 1998, 1155-1167, vol. 78, No. 9.
Liu, G., et al, “Neph1 and Nephrin Interaction in the Slit Diaphragm is an Important Determinant of Glomerular Permeability,”The Journal of Clinical Investigation, 2003, 209-221, vol. 112, No. 2.
Nose, A., et al., “A Novel Cadherin Cell Adhesion Molecule: Its Expression Patterns Associated with Implantation and Organogenesis of Mouse Embryos,”Journal of Cell Biology, 1986, 2649-2658, vol. 103, No. 6.
Palacios, J., et al., “Anomalous Expression of P-Cadherin in Breast Carcinoma. Correlation with E-Cadherin Expression and Pathological Features,”American Journal of Pathology, 1995, 605-612, vol. 146, No. 3.
Radice, G., et al., “Precocious Mammary Gland Development in P-Cadherin-Deficient Mice,”The Journal of Cell Biology, 1997, 1025-1032, vol. 139, No. 4.
Rasbridge, S., et al., “Epithelial (E-) and Placentae (P-) Cadherin Cell Adhesion Molecule Expression in Breast Carcinoma,”Journal of Pathology, 1993, 245-250, vol. 169, No. 2.
Sanders, D., et al., “Aberrant P-Cadherin Expression is a Feature of Clonal Expansion in the Gastrointestinal Tract Associated with Repair and Neoplasia,”Journal of Pathology, 2000, 526-530, vol. 190, No. 5.
Seikagaku, 2002, 871, vol. 74, No. 8.
Shimoyama, Y., et al., “Cadherin Cell-adhesion Molecules in Human Epithelial Tissues and Carcinomas,”Cancer Res. (1989) 2128-2133, vol. 49.
Shimoyama, Y., “Molecular Cloning of a Human Ca2+-dependent Cell-Cell Adhesion Molecule Homologous to Mouse Placental Cadherin: Its Low Expression in Human Placental Tissues,”J. Cell Biology(1989) 17888-1794, vol. 109.
Stefansson, I.M., et al., “Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer,”J. Clin. Oncology(2004), 1242-1252, vol. 22, No. 7.
Takeichi, M., “Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator,”Science(1991), 1451-1455, vol. 251.
Williams, H., et al., “Expression of Cadherins and Catenins in Oral Epithelial Dysplasia and Squamous Cell Carcinoma,”Journal of Oral Pathology and Medicine, 1998, 308-317, vol. 27, No. 7.
Yagi, T., et al., “Cadherin Superfamily Genes: Functions, Genomic Organization, and Neurologic Diversity,”Genes Dev., (2000) 1169-1180, vol. 14.
Yasui, W., et al, “Expression of P-Cadherin in Gastric Carcinomas and its Reduction in tumor Progression,”International Journal of Cancer, 1993, 49-52, vol. 54, No. 1.
Bauer Christopher Todd
Bourner Maureen Jeri
Boyle Melanie
Casperson Gerald Fries
Griggs David William
Agouron Pharmaceuticals , Inc.
Bristol Lynn
Shoarinejad Fariba
Tidwell Jeffrey H.
LandOfFree
P-cadherin antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P-cadherin antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P-cadherin antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619833